RECEIVED CENTRAL FAX CENTER

DEC 2 2 2006

## PATENT/Docket No. PC20702C

Appl. No. 10/801897 Filing Date: March 15, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

J-L Dasseux et al.

Serial Number

10/801897

Filed

March 15, 2004

For

APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT

DYSLIPIDEMIC DISORDERS

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

## COMMUNICATION

Sir:

The Assignee(s) for the above-referenced United States Patent Application has been stated incorrectly in the Pair system and on the published application as "Esperion Therapeutics, Inc." This communication is to correct the Assignee(s). The correct Assignee(s) of record are located at Reel 012153/ Frame 0214, and are as follows. Please ensure the USPTO's records and the printed patent reflect this information.

Dasseux, Jean-Louis, 7898 Huron Oak Drive, Brighton, Michigan 48116 Sekul, Renate, Wichernstr. 13, Ladenburg, Germany D-685 Buttner, Klaus, Eichendorffstr. 6, Epfenbach, Germany D-746 Cornut, Isabelle, 516 Route Du Foron, Cry, Reignier, France F-74 Metz, Gunther, Hagellachstr. 41, Heidelberg, Germany 69124 Dufourcq, Jean, 7, Ru Jacques Prevert, Pessac, France F-336

If there is a further discrepancy please contact the undersigned.

Respectfully submitted.

Registration No. 31820

Pfizer Inc., Patent Department 2800 Plymouth Road

Ann Arbor, MI 48105

Telephone No. (734) 622-5940 Telefax No. (734) 622-1553

FORM AMEND Rev. 5/27/03

12-22-2006

PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pacetwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/08 1897 TRANSMITTAL Filing Date March 15, 2004 First Named Inventor **FORM** RECEIVED J-L Dasseux Art Link CENTRAL FAX CENTER 1654 Examiner Name Jeffrey E. Russel (to be used for all correspondence after initial filing) Attorney Docket Number PC20702C Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Repty Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): PTOL-85 (Issue Fee Payment) - 1 Page Request for Refund Express Abandonment Request Communication - 1 Page Fee Address Indication Form - 1 Page CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pfizer Inc Signature Printed name Martha A. Gemmill Date Reg. No. 31820 **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature house Valerie Schipper Date Typed or printed name

This collection of Information is required by 37 CFR 1.5. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradement Office, U.S. Department of Commission, P.O. Box 1450, Alexandria, VA. 2343-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## PART B - FEE(S) TRANSMITTAL

RECEIVED CENTRAL FAX CENTER

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

DEC 2 2 2006

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance frees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Pfizer Inc., Patent Department 2800 Plymouth Road Ann Arbor, MI 48105

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I acreby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FBB address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Valerie Schipper (Dopositor's name) Valeir Sampper (Signal

APPLN. TYPE Sh nonprovisional  EXAMINER  RUSSEI, Jeffrey Change of correspondence ac  FR 1.363).  Change of correspondence active som PTO/SB/122)  Tee Address indication	NO  / E: ddress or indication of control of the con	\$1400 ART UNIT 1654 of "Fee Address" (37	JOHN-LOUIS DESSEUX USE TO Treat Dys PUBLICATION FEE DUB \$300 CLASS-SUBCLASS 514-012000 2. For printing on the pu	01/05 slipidemic D 01 FC PREV. PAID SSUE \$0	/2007 T <b>isorde</b> :1501	EY DOCKET NO.   C20702C BESHAH2 080806 IS 1409.00 D OTAL FERSY DAY 1	)A	108010 TE
APPLN. TYPE SN nonprovisional  EXAMINER  RUSSEI, Jeffrey Change of correspondence ac FR 1.363).  Change of correspondence ac FR 1.563.  Change of correspondence ac FR 1.363.  Maddress form PTO/SB/122.  Market is required.	NO  ALL ENTITY  NO  E:  ddress or indication of translated of the control of the	\$1400 ART UNIT 1654 of "Fee Address" (37	PUBLICATION FEE DUE \$300  CLASS-SUBCLASS 514-Q12000	Slipidemic D 01 FC PREV. PAID ISSUE	/2007 T isorde :1501	BESHAH2 000000 rs 1400.00 D otal feesydes	34 230455 A DATE D	Æ
Applipoprot  APPLN. TYPE SA  nonprovisional  EXAMINER  RUSSEI, Jeffrey Change of correspondence as FR 1.363).  Change of correspondence and free some PTO/SB/122)  The Address form PTO/SB/122 or n Number is required.	NO  / E: ddress or indication of control of the con	\$1400 ART UNIT 1654 of "Fee Address" (37	PUBLICATION FEE DUE \$300 CLASS-SUBCLASS 514-012000	Slipidemic D 01 FC PREV. PAID ISSUE	isorde : 1591	TS 1400.00 D OTAL FEESY DIE D	A DATE D	Æ
APPLN. TYPE She nonprovisional  EXAMINER  RUSSEI, Jeffrey Change of correspondence as FR 1.363).  Change of correspondence and free short PTO/SB/47; Rev 03-02 or n Number is required.	NO  / E: ddress or indication of control of the con	\$1400 ART UNIT 1654 of "Fee Address" (37	PUBLICATION FEE DUE \$300 CLASS-SUBCLASS 514-012000	Slipidemic D 01 FC PREV. PAID ISSUE	isorde : 1591	TS 1400.00 D OTAL FEESY DIE D	A DATE D	æ
APPLN. TYPE She nonprovisional  EXAMINER  RUSSEI, Jeffrey Change of correspondence as FR 1.363).  Change of correspondence and Address form PTO/SB/122)  2 "Fee Address" indication PTO/SB/47; Rev 03-02 or n Number is required.	NO  / E: ddress or indication of control of the con	\$1400 ART UNIT 1654 of "Fee Address" (37	PUBLICATION FEE DUE \$300 CLASS-SUBCLASS 514-012000	PAEV. PARTISSUE	:1591	1400.00 D	DATE D	لـــــــا
RUSSel, Jeffrey Change of correspondence as FR 1.363).  Change of correspondence Address form PTO/SB/122)  d'Fee Address' indication PTO/SB/47; Rev 03-02 or n Number is required.	NO / E ddress or indication of the control of t	\$1400 ART UNIT 1854 of "Fee Address" (37	\$300 CLASS-SUBCLASS 514-012000		<del>РЕ</del> В Т		·	
Russel, Jeffrey Change of correspondence as FR 1.363).  Change of corresponden Address form PTO/SB/122)  Tee Address indication PTO/SB/47; Rev 03-02 or n Number is required.	/ E : ddress or indication of consideress (or Change attached.	ART UNIT  1654 of "Fee Address" (37	CLASS-SUBCLASS 514-Q12000	\$0		\$1700	01/03	2007
Russel, Jeffrey Change of correspondence as R 1.363).  Change of corresponden Address form PTO/SB/122)  Fee Address indication PTO/SB/47; Rev 03-02 or n Number is required.	ddress or indication of co address (or Chang attached.	1654 of "Fee Address" (37	514-012000	-				
Change of correspondence as R 1.363).  Change of corresponden Address form PTO/SB/122)  Tee Address indication PTO/SB/47; Rev 03-02 or n Number is required.	ddress or indication of co address (or Chang attached.	of "Fee Address" (37						
FR 1.363).  Change of correspondent Address form PTO/SB/122)  The Address form PTO/SB/122)  The Address findication PTO/SB/47; Rev 03-02 or n Number is required.	ce address (or Chang attached.	•	2. For printing on the p					
Change of correspondent Address form PTO/SB/122)  The Address indication PTO/SB/47; Rev 03-02 or n Number is required.	auschool (or "Fee Address" is	e of Correspondence		nent front page, lis	1			
"Fee Address" indication PTO/SB/47; Rev 03-02 or n Number is required.	(or "Fee Address" Is	Change of correspondence address (or Change of Correspondence			attorneys	1 Mertha A. Ge	ammill	
ASSIGNEE NAME AND RI	Tee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Continuer			firm (having as a gent) and the name neys or agents. If n trinted.	members s of up to o name is	2 Charles W. A	shbmok	
. MOSGI WE 14 SHIELD ICE	ESIDENCE DATA I	O DE DEDINTED ON T	UE DATENT (i-t t					
PLEASE NOTE: Unless an					a ia klemti	fied below the dom	ment has been	Slad San
PLEASE NOTE: Unless an recordation as set forth in 37	CFR 3.11. Complet						man nes occu	IIKA KI
(A) NAME OF ASSIGNEE Jeen Louis Dasseux, Renat	te Sekul Kinus Pud		(B) RESIDENCE: (CITY lichigan, Germany, Germ					
	·	•	acagair, Germany, Germ	mily, Flance, Ge	meny, Fr	au ice		
sabelle Cornut, Gunther M							_	
case check the appropriate ass	agnee category or ca	legaries (will not be pri	nted on the patent):	individual 🐸 Cor	poration o	r other private group	entity U Gov	emment
The following fee(s) are sub-	unitted:	4b.	Psyment of Foc(s): (Pleas	e first reapply any	previous	ly paid insue fee she	wa above)	
Lisue Fee			A check is enclosed.					
			☐ Payment by credit card. Form PTO-2038 is attached. ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any					
Advance Order - # of Copies			overpayment, to Deposi	suthonized to charge t Account Number	the requi	red fee(s), any defici 55 (enclose an er	iency, or credit a ttra copy of this	my form).
Change in Entity Status (fro	m status indicated ab	ove)	<u> </u>					<del></del>
a. Applicant claims SMA			b. Applicant is no longe	r claiming SMALI	. ENTITY	status. See 37 CFR	1.27(g)(2).	
TE: The Issue Fee and Public rest as shown by the records	cation Fee (if require of the United States)	d) will not be accepted Patent and Trademark (	from anyone other then the Office.	applicant; a regist	ered attorn	cy or agent; or the a	ssignee or other	perty in
Authorized Signature	arthale	Gumil	l	Date [2	121	106		<del></del>
Typod or printed name <u>Martt</u>	na A. Gamm⊪	<del>-</del>		Registration No.	31820	<i>(</i>		
s collection of information is application. Confidentiality is mitting the completed applica- form and/or suggestions for	required by 37 CFR	1.311. The information	is required to obtain or ret	in a henefit by the	mblic mb	ich is to file ( 1 l	the Heppine	

Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 07/06) Approved for use through 04/30/2007.

OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE